JP2013537418A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537418A5 JP2013537418A5 JP2013524306A JP2013524306A JP2013537418A5 JP 2013537418 A5 JP2013537418 A5 JP 2013537418A5 JP 2013524306 A JP2013524306 A JP 2013524306A JP 2013524306 A JP2013524306 A JP 2013524306A JP 2013537418 A5 JP2013537418 A5 JP 2013537418A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- heavy chain
- amino acid
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 102000015696 Interleukins Human genes 0.000 claims description 6
- 108010063738 Interleukins Proteins 0.000 claims description 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37448910P | 2010-08-17 | 2010-08-17 | |
| US61/374,489 | 2010-08-17 | ||
| PCT/AU2011/000155 WO2011100786A1 (en) | 2010-02-17 | 2011-02-17 | Compositions and methods for targeting type 1 interferon producing cells |
| AUPCT/AU2011/000155 | 2011-02-17 | ||
| PCT/AU2011/001056 WO2012021934A1 (en) | 2010-08-17 | 2011-08-17 | Humanized anti-interleukin 3 receptor alpha chain antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013268626A Division JP5933517B2 (ja) | 2010-08-17 | 2013-12-26 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013537418A JP2013537418A (ja) | 2013-10-03 |
| JP2013537418A5 true JP2013537418A5 (enExample) | 2013-11-14 |
| JP5524418B2 JP5524418B2 (ja) | 2014-06-18 |
Family
ID=45604615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013524306A Active JP5524418B2 (ja) | 2010-08-17 | 2011-08-17 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
| JP2013268626A Active JP5933517B2 (ja) | 2010-08-17 | 2013-12-26 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013268626A Active JP5933517B2 (ja) | 2010-08-17 | 2013-12-26 | ヒト化抗インターロイキン３レセプターα鎖抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8569461B2 (enExample) |
| EP (2) | EP2778175B1 (enExample) |
| JP (2) | JP5524418B2 (enExample) |
| KR (1) | KR101347688B1 (enExample) |
| CN (1) | CN103025761B (enExample) |
| CA (1) | CA2805176C (enExample) |
| DK (1) | DK2606069T3 (enExample) |
| ES (1) | ES2506340T3 (enExample) |
| GB (1) | GB2488091B (enExample) |
| IL (1) | IL225631A (enExample) |
| NZ (1) | NZ604510A (enExample) |
| PL (1) | PL2606069T3 (enExample) |
| WO (1) | WO2012021934A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2305300T3 (pl) * | 2008-07-10 | 2016-09-30 | Kompozycja farmaceutyczna do leczenia i zapobiegania nowotworowi | |
| US20100209341A1 (en) * | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
| EP2426148B1 (en) | 2009-04-27 | 2015-08-05 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
| HUE059815T2 (hu) * | 2012-05-18 | 2022-12-28 | Aptevo Res & Development Llc | Bispecifikus SCFV immunofuziós (BIF) kötõdés a CD123-hoz és a CD3-hoz |
| WO2014138819A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Agents that neutralize il-3 signaling and uses thereof |
| WO2014138805A1 (en) * | 2013-03-14 | 2014-09-18 | Csl Limited | Anti il-3r alpha agents and uses thereof |
| EP2839842A1 (en) | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
| RS60305B1 (sr) * | 2014-09-05 | 2020-07-31 | Janssen Pharmaceutica Nv | Agensi koji vezuju cd123 i njihove upotrebe |
| TN2017000275A1 (en) * | 2015-01-23 | 2018-10-19 | Sanofi Sa | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| TW201709932A (zh) * | 2015-06-12 | 2017-03-16 | 西雅圖遺傳學公司 | Ｃｄ１２３抗體及其共軛物 |
| CA2990076A1 (en) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| US10744205B2 (en) * | 2015-06-23 | 2020-08-18 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodies |
| SI3313884T1 (sl) | 2015-06-29 | 2021-04-30 | Immunogen, Inc. | Protitelesa proti CD123 ter njihovi konjugati in derivati |
| CN116059390A (zh) | 2016-03-24 | 2023-05-05 | 拜耳制药股份公司 | 具有酶促可裂解基团的细胞毒性活性物质的前药 |
| EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
| PH12019500609B1 (en) * | 2016-09-21 | 2024-02-21 | Aptevo Res & Development Llc | Cd123 binding proteins and related compositions and methods |
| CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
| RU2761390C2 (ru) | 2016-12-21 | 2021-12-07 | Байер Фарма Акциенгезельшафт | Конъюгаты связующего и активного вещества (adc), имеющие ферментативно расщепляемые группы |
| US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
| CA3006798A1 (en) | 2017-06-02 | 2018-12-02 | Pfizer Inc. | Antibodies specific for flt3 and their uses |
| EP3746079A1 (en) | 2018-01-31 | 2020-12-09 | Bayer Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| MX2021010857A (es) * | 2019-03-11 | 2021-12-15 | Janssen Biotech Inc | Anticuerpos biespecificos anti-v(beta17)/anti-cd123. |
| WO2020227071A1 (en) | 2019-05-04 | 2020-11-12 | Inhibrx, Inc. | Cd123-binding polypeptides and uses thereof |
| WO2021013693A1 (en) | 2019-07-23 | 2021-01-28 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (adcs) with nampt inhibitors |
| WO2022056192A1 (en) | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
| AU2021414400A1 (en) | 2020-12-31 | 2023-08-17 | Innate Pharma | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| US20250326818A1 (en) * | 2021-08-06 | 2025-10-23 | Universität Basel | Discernible cell surface protein variants for use in cell therapy |
| JP7747911B2 (ja) | 2022-05-27 | 2025-10-01 | サノフイ | ＮＫｐ４６に結合するナチュラルキラー（ＮＫ）細胞エンゲージャー及びＦＣエンジニアリングを有するＢＣＭＡ変異体 |
| EP4296280A1 (en) * | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
| WO2024105206A1 (en) | 2022-11-17 | 2024-05-23 | Vincerx Pharma Gmbh | Antibody-drug-conjugates cleavable in a tumor microenvironment |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0672068A4 (en) | 1992-09-25 | 1997-02-26 | Commw Scient Ind Res Org | TARGET MOLECULES BINDING POLYPEPTIDES. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| US6177078B1 (en) * | 1995-12-29 | 2001-01-23 | Medvet Science Pty Limited | Monoclonal antibody antagonists to IL-3 |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DE69942021D1 (de) | 1998-04-20 | 2010-04-01 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| JP4469933B2 (ja) | 1998-05-06 | 2010-06-02 | ジェネンテック， インコーポレイテッド | イオン交換クロマトグラフィによるタンパク質精製 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1914244E (pt) | 1999-04-09 | 2013-07-26 | Kyowa Hakko Kirin Co Ltd | Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico |
| US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
| CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| DE602004026470D1 (de) | 2003-11-05 | 2010-05-20 | Roche Glycart Ag | Fc-rezeptor und effektorfunktion |
| US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
| KR100627856B1 (ko) * | 2004-06-28 | 2006-09-25 | 에스케이 텔레콤주식회사 | 착신측 교환기를 이용하여 멀티미디어 링백톤 서비스를제공하는 방법 및 시스템 |
| US20070135620A1 (en) | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CN101098890B (zh) * | 2004-11-12 | 2012-07-18 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| WO2006082406A2 (en) | 2005-02-03 | 2006-08-10 | Antitope Limited | Human antibodies and proteins |
| US20060263367A1 (en) | 2005-05-23 | 2006-11-23 | Fey Georg H | Bispecific antibody devoid of Fc region and method of treatment using same |
| WO2007019620A1 (en) | 2005-08-15 | 2007-02-22 | Arana Therapeutics Limited | Engineered antibodies with new world primate framework regions |
| US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| CA2706337A1 (en) * | 2007-12-06 | 2009-06-11 | Csl Limited | Method of inhibition of leukemic stem cells |
| JP2012503982A (ja) * | 2008-09-26 | 2012-02-16 | ワイス・エルエルシー | 適合性ディスプレイベクター系 |
| US20100209341A1 (en) * | 2009-02-18 | 2010-08-19 | Csl Limited | Treatment of chronic inflammatory conditions |
| EP2426148B1 (en) | 2009-04-27 | 2015-08-05 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-3ra antibody for use in treatment of blood tumor |
| NZ604510A (en) | 2010-08-17 | 2013-10-25 | Csl Ltd | Dilutable biocidal compositions and methods of use |
-
2011
- 2011-06-07 NZ NZ604510A patent/NZ604510A/xx unknown
- 2011-08-17 ES ES11817577.7T patent/ES2506340T3/es active Active
- 2011-08-17 DK DK11817577.7T patent/DK2606069T3/da active
- 2011-08-17 EP EP14165984.7A patent/EP2778175B1/en active Active
- 2011-08-17 WO PCT/AU2011/001056 patent/WO2012021934A1/en not_active Ceased
- 2011-08-17 EP EP11817577.7A patent/EP2606069B1/en active Active
- 2011-08-17 US US13/256,926 patent/US8569461B2/en active Active
- 2011-08-17 KR KR1020137002451A patent/KR101347688B1/ko active Active
- 2011-08-17 GB GB1211289.2A patent/GB2488091B/en active Active
- 2011-08-17 PL PL11817577T patent/PL2606069T3/pl unknown
- 2011-08-17 CA CA2805176A patent/CA2805176C/en active Active
- 2011-08-17 CN CN201180036658.2A patent/CN103025761B/zh active Active
- 2011-08-17 JP JP2013524306A patent/JP5524418B2/ja active Active
-
2013
- 2013-04-08 IL IL225631A patent/IL225631A/en active IP Right Grant
- 2013-09-24 US US14/035,805 patent/US20140086912A1/en not_active Abandoned
- 2013-12-26 JP JP2013268626A patent/JP5933517B2/ja active Active
-
2015
- 2015-04-03 US US14/678,356 patent/US10047161B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013537418A5 (enExample) | ||
| JP2014076062A5 (enExample) | ||
| US12448423B2 (en) | Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains | |
| Michailidou et al. | Allergic aspects of IgG4-related disease: implications for pathogenesis and therapy | |
| US20210171596A1 (en) | Untargeted and targeted il-10 fc-fusion proteins | |
| US20190070262A1 (en) | Interleukin-18 variants and methods of use | |
| JP2009502171A5 (enExample) | ||
| JP2021521784A (ja) | ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用 | |
| JP2009521909A5 (enExample) | ||
| JP2008542278A5 (enExample) | ||
| AU2020283817A1 (en) | TIGIT and PD-1/TIGIT-binding molecules | |
| US9783605B2 (en) | Pan-ELR+ CXC chemokine antibodies | |
| EP2970447B1 (en) | Pan-elr+ cxc chemokine antibodies | |
| RU2015107889A (ru) | Композиция, содержащая два антитела, сконструированных так, чтобы они обладали пониженной и повышенной эффекторной функцией | |
| JP2010511388A5 (enExample) | ||
| CN115350275A (zh) | 抗pvrig抗体和使用方法 | |
| JP2016538830A5 (enExample) | ||
| MX2014008101A (es) | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17. | |
| JP2012524524A5 (enExample) | ||
| IL322617A (en) | Engineered antibodies against IL-2 | |
| CA3250092A1 (en) | CD3/BCMA/CD38 TRISACIFICAL ANTIBODIES | |
| RU2797536C2 (ru) | Варианты интерлейкина-18 и способы их применения | |
| HK40117648A (zh) | Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途 | |
| HK40119780A (zh) | Cd3/bcma/cd38三特异性抗体 | |
| AU2013203262B2 (en) | Humanized anti-CXCR5 antibodies, derivatives thereof and their uses |